News | July 09, 2024
Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher
Shares and American Depositary Shares of Olink for $26.00 per Share
Shares and American Depositary Shares of Olink for $26.00 per Share
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Increased capability to produce medicines for challenging diseases including cancer
The refrigerators and freezers are the latest offering in Thermo Fisher’s industry-leading portfolio of smart lab solutions
Advances clinical research capabilities with leading regulatory grade registries platform
Testing supporting allergy diagnosis now accessible to more people in more communities
Bourgoin early development hub broadens offerings for oral solid dose formulations
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Subscribe To Our Newsletter & Stay Updated
